Journal
PEDIATRIC BLOOD & CANCER
Volume 65, Issue 9, Pages -Publisher
WILEY
DOI: 10.1002/pbc.27089
Keywords
acute myelogenous leukemia (AML); adolescents and young adults (AYA); clinical trials; prognosis; survival
Categories
Funding
- National Cancer Institute, National Institutes of Health
- Cancer Center Support [CA21765]
- American Lebanese Syrian Associated Charities
Ask authors/readers for more resources
The incidence of acute myelogenous leukemia (AML) increases progressively with age. Favorable genetic mutations are most prevalent in children, and unfavorable profiles increase proportionately in adolescents and young adults (AYA) and into later adulthood. Survival rates of AYA have improved over recent decades to 50-60%, but their accrual to clinical trials remains poor. In contrast to AYA with acute lymphoblastic leukemia, the prognostic benefit for AYA with AML enrolled in pediatric compared with adult trials is minor and only seen when different protocols are used. The distinctive needs of AYA, including intensive psychological services, call for their treatment within specialized centers that offer complex supportive care.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available